In addition to the tropism of MV to specific cell receptors, other underlying mechanisms contribute to the tumor selectivity of MV vaccine strains, such as defects in the IFN antiviral response pathway, which is often dysregulated in tumor cells to facilitate their escape from the host immune system (37). The gene discussed is IFNA1; the disease is neoplasm.